Abstract
Prevalence estimates of autism spectrum disorder (henceforth autism) in Latin America thus far have been limited by a lack of reliable population-level data. We analyzed autism school prevalence across 29 Chilean health service regions for students aged 6–18 years, standardized by age and sex. We validated these results using electronic health records from one of Chile’s largest regional health service, the Servicio de Salud Araucania Sur (SSAS). We then projected Bayesian prevalences, reporting nationally, and by health service, ethnicity, immigration background, and rurality. We found a standardized national school autism prevalence of 0.46% (95% CI, 0.46%-0.47%), with boys having six times higher odds of autism than girls (OR 6.10 [95%CI: 5.82–6.41]). The sex - and age-adjusted clinical prevalence in the SSAS trust was 1.22% (95% CI: 1.16%-1.28%) and the projected Bayesian national autism prevalence was 1.31% (95% Credible Interval: 1.25%-1.38%). Our results indicate a higher autism prevalence than previously reported in the south of the Araucania region with observed disparities in prevalence across sex, ethnic groups, and health services.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received no funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Cambridge Psychology Department Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is not available due to privacy concerns
